BenzingaAugust 24, 2026 at 2:33 AM NY11 days ago

Gilead’s Trodelvy-Keytruda Combo Gets EU Approval for Metastatic Breast Cancer

Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the European Commission (EC) has granted marketing authorization for Trodelvy® (sacituzumab govitecan-hziy) in combination with Keytruda® (pembrolizumab) for the

Read the Full Story at the Source

The summary here comes from the news provider; the rest of the article lives on the publisher's site — Benzinga

Read at Source

Companies in This Story

GILDGilead Sciences, Inc150.85− 0.24%

Companies in This Story

Related Stories